用调节器治疗囊性纤维化症的未解决的挑战
Federica Corrao1,2, Mairead Kelly-Aubert2, Isabelle Sermet-Gaudelus2,3,4,5
1Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy.
Expert review of respiratory medicine
|May 16, 2024
概括
高效的调节器疗法 (HEMT) 已经改变了囊性纤维化 (CF) 护理,改善了肺功能和生存率. 然而,在接入,特定人群和长期影响方面,仍然存在挑战.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 高效调制剂疗法 (HEMT) 代表了囊性纤维化 (CF) 治疗的重大进展.
- 这些疗法重新塑造了CF (pwCF) 患者的治疗环境.
研究的目的:
- 评估HEMT对pwCF生活的影响.
- 确定特定人群的治疗挑战,包括幼儿.
- 突出目前在HEMT治疗中的知识差距.
主要方法:
- 采用了全面的文献搜索策略.
- 分析的重点是HEMT的疗效,挑战和未来的研究需求.
主要成果:
- HEMT是基因型特定的,约10%的pwCF是不合格的.
- 疗法改善肺功能,生活质量和生存率,将CF转移到成年人的疾病.
- 关于长期疗效,副作用,并发症,药物相互作用以及怀孕/母乳养期间使用的知识差距存在.
结论:
- 基因型特定的HEMT治疗推动了个性化医疗方法.
- 进一步的研究对于解决全球长期结果,安全和公平获取至关重要.
- 迫切需要研究HEMT在怀孕和哺乳期间的使用情况.
相关概念视频
Cystic Fibrosis: Management
155
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
155
Cystic Fibrosis: Pathogenesis
222
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
222
Antiasthma Drugs: Leukotriene Modifiers
281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
281
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
COPD: Management Using Bronchodilators and Corticosteroids
197
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
197
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
277
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
277


